125602-76-8

Upstream product

• 2969-81-5 Ethyl 4-bromobutyrate 
• 58258-01-8 4-diphenylmethoxypiperidine 
• 133993-06-3 methyl 4-diphenylmethoxypiperidine-1-carboxylate 
• 75250-52-1 4-hydroxy-piperidine-1-carboxylic acid methyl ester 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 65214-84-8 ethyl 4-(diphenylmethoxy)-1-piperidinecarboxylate 
• 147-20-6 diphenylpyraline 
• 3153-36-4 4-chloro-butyric acid ethyl ester 

Downstream Products

• 215530-55-5 4-(Diphenylmethoxy)-1-piperidinebutanol 
• 133993-23-4 4-(4-Benzhydryloxy-piperidin-1-yl)-butyric acid 

Relevant academic research and scientific papers

Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Aβ1-42 aggregation for Alzheimer's disease therapeutics

With the goal of developing Alzheimer's disease therapeutics, we have designed and synthesized new piperidine derivatives having dual action of acetylcholinesterase (AChE) and beta-amyloid peptide (Aβ) aggregation inhibition. For binding with the catalytic site of AChE, an ester with aromatic group was designed, and for the peripheral site, another aromatic group was considered. And for intercalating amyloid-beta oligomerization, long and linear conformation with a lipophilic group was considered. The synthetic methods employed for the structure with dual action depended on alcohols with an aromatic ring and the substituted benzoic acids, which are esterificated in the last step of the synthetic pathway. We screened these new derivatives through inhibition tests of acetylcholinesterase, butyrylcholinesterase (BChE), and Aβ1-42 peptide aggregation, AChE-induced Aβ1-42 aggregation. Our results displayed that compound 12 showed the best inhibitory potency and selectivity of AChE, and 29 showed the highest selectivity of BChE inhibition. Compounds 15 and 12 had inhibitory activities against Aβ1-42 aggregation and AChE-induced Aβ aggregation. In the docking model, we confirmed that 4-chlorobenzene of 12 plays the parallel π-π stacking against the indole ring of Trp84 in the bottom gorge of AChE. Because the benzyhydryl moiety of 12 covered the peripheral site of AChE in a funnel-like shape, 12 showed good inhibitory potency against AChE and could inhibit AChE-induced Aβ1-42 peptide aggregation.

Amphoteric drugs. I. Synthesis and antiallergic activity of [4-(diphenylmethoxy)piperidino]-, [4-(diphenylmethyl)piperazinyl]- and [4-(diphenylmethylene)piperidino]alkanoic acid derivatives

A simple method of transforming classical antihistaminics into nonsedative antiallergic agents with strong effects in rat models is described. Various [4-(diphenylmethoxy)piperidinol - (series A), [4-(diphenylmethyl)piperazinyl]- (series B) and [4-(diphenylmethylene)piperidino]alkanoic acid derivatives (series C) were synthesized and examined for antiallergic activities and effects on the central nervous system (CNS), in comparison with the corresponding N-methyl derivatives (1a-c). N-Alkylcarboxylic acids (5a-c) showed stronger inhibitory effects on compound 48/80-induced lethality in rats than the corresponding N-methyl derivatives (1a-c). In particular, N-alkylcarboxylic acids (5a) in series A exhibited approximately 100-fold stronger inhibitory effects than 1a, and were the least effective in prolonging the sleeping time on hexobarbital-induced anesthesia in mice in all series. As a result of chemical modification in series A, it was found that introduction of a methyl group at the para-position on one benzene ring in the (diphenylmethoxy)piperidine system effectively reduced CNS side-effects without reducing antiallergic activity. (+)-3-[4-[(4-Methylphenyl)phenylmethoxy] piperidinol propionic acid ((+)-51), an optically active isomer of 51, exhibited a stronger antiallergic effect (ED50 = 0.17 mg/kg, p.o.) than ketotifen and terfenadine in the 48 h homologous passive cutaneous anaphylaxis (PCA) test, and moreover exhibited no CNS side-effects, such as prolongation of the sleeping time on hexobarbital-induced anesthesia, at an oral dose of 30 mg/kg. Compound (+)-51 was thus proved to be a promising candidate as a nonsedative antiallergic agent.

GABA uptake inhibitors. Syntheses and structure-activity studies on GABA analogues containing diarylbutenyl and diarylmethoxyalkyl N-substituents

A number of analogues of GABA or β-alanine containing 4,4-diphenyl-3-butenyl (DPB), benzhydryl ethyl ether (BEE), or benzhydryl propyl ether N-substituents have been synthesized and tested as inhibitors of synaptosomal GABA uptake. Whereas the N-DPB and N

Piperdine and piperazine derivatives, and antihistaminic pharmaceutical compositions containing the same

Disclosed is a compound represented by Formula (I): STR1 wherein Ar1, Ar2, n, A, B and Z are as defined in claims. Disclosed are also a process for preparing the compound and pharmaceutical compositions containing the compound. The compound has an antihistamic and antiallergic effect.